Vivani Medical IncNASDAQ:VANI
- LAST PRICE1.0000
- TODAY'S CHANGE (%)0.0500 (5.2632%)
- Bid / Lots0.9430/ 8
- Ask / Lots1.0300/ 1
- Open / Previous Close1.0008 / 0.9500
- Day Range
- 52 Week Range
- Volume46,871
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | VANI |
|---|---|---|
| 09:39 ET | 699 | 1.0299 |
| 09:45 ET | 300 | 1.0245 |
| 09:48 ET | 668 | 1.0101 |
| 09:54 ET | 150 | 0.9908 |
| 10:57 ET | 100 | 0.9728 |
| 11:02 ET | 1510 | 0.9963 |
| 11:22 ET | 100 | 0.9999 |
| 11:47 ET | 2451 | 0.9899 |
| 11:54 ET | 435 | 0.9899 |
| 11:58 ET | 500 | 0.9727 |
| 12:00 ET | 100 | 1 |
| 12:23 ET | 916 | 0.9964 |
| 12:45 ET | 25424 | 0.97 |
| 02:00 ET | 100 | 1 |
| 02:15 ET | 100 | 1 |
| 02:26 ET | 400 | 1 |
| 02:56 ET | 200 | 1 |
| 03:05 ET | 4899 | 1 |
| 03:12 ET | 262 | 1 |
| 03:14 ET | 207 | 1.0199 |
| 03:34 ET | 294 | 1 |
| 03:38 ET | 123 | 1 |
| 03:52 ET | 996 | 1.0148 |
| 03:56 ET | 500 | 1 |
| 03:57 ET | 688 | 1 |
| 03:59 ET | 1001 | 1 |
Sep 7, 2023
Vivani Medical to Present at the Boulder Peptide Symposium, from 6:00AM ET on Thursday Sep 07, 2023 by Dow Jones
6:00AM ET on Thursday Sep 07, 2023 by Dow Jones
Sep 5, 2023
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Vivani Medical Inc | 48.3M | -2.5x | --- |
Rewalk Robotics Ltd | 43.6M | -2.3x | --- |
United Health Products Inc | 59.1M | -35.5x | --- |
Lucid Diagnostics Inc | 64.7M | -1.0x | --- |
Delcath Systems Inc | 62.9M | -1.2x | --- |
DermTech Inc | 52.5M | -0.4x | --- |
Company Information
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. NanoPortal implant technology's initial focus is on peptide therapeutics for the treatment of patients with metabolic diseases. It operates through two segments: Biopharm Division and Neuromodulation Division. Its pipeline product candidates include NPM-119, NPM-159, NPM-139 and OKV-119. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. NPM-159 is in feasibility testing for the treatment of non-alcoholic steatohepatitis (NASH). It is also in the development of neurostimulation systems to help patients recover critical body functions.
Contact Information
- Headquarters
- 5858 Horton Street, Suite 280EMERYVILLE, CA, United States 94608
- Phone
- 818-833-5000
- Fax
- 818-833-5067
Executives
- Non-Executive Independent Chairman of the Board
- Gregg Williams
- Chief Executive Officer, Director
- Adam Mendelsohn
- Chief Financial Officer
- Brigid Makes
- Chief Operating Officer
- Truc Le
- Chief Business Officer
- Donald Dwyer
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $48.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 50.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.59 |
EPS | $-0.40 |
Book Value | $0.87 |
P/E Ratio | -2.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
